October 28, 2026
Formation Bio, an AI-native drug company, announced a $600 million investment fund on Wednesday to buy clinical-stage medicines that have stalled inside other companies’ pipelines and push them through trials. Why it matters: most AI drug startups chase discovery — finding new molecules. Formation is betting the bigger bottleneck is the long, expensive clinical-development stage where most drugs actually fail.
What happened
The Formation Bio Drug Development Accelerator Fund launches with $600 million in capital commitments. Its limited partners include research foundations, institutional endowments, hospitals and philanthropic organizations. Formation Bio runs the fund as general partner through a wholly owned subsidiary and has committed its own capital alongside the outside investors.
The plan is to acquire or in-license 10 to 15 drug programs over the next three to five years. Forbes, which reported the launch the same day, noted the company has already licensed two candidates.
How the model works
Formation targets Phase 1 and Phase 2 programs from pharmaceutical companies and biotechs, prioritizing diseases with substantial unmet need and limited active development, with major clinical milestones targeted within two to four years of acquisition. Each funded program sits in its own standalone corporate entity, so one drug’s economics stay separate from the next, while all of them share Formation’s central development team, technology and clinical operating infrastructure — the company’s “hub-and-spoke” model.
The fund finances only Formation’s own portfolio. Once a program makes meaningful clinical progress, the company expects to partner it with a pharmaceutical company for commercialization or co-commercialization. CEO Benjamine Liu said the structure expands the number of promising drugs the company can pursue and creates paths to liquidity without selling the parent company.
Why it matters
Promising medicines routinely get stranded when a sponsor runs out of money or changes strategy — not because the science failed. A $600 million pool dedicated to rescuing those assets is a real test of whether an AI-supported development operation can move drugs through trials faster or more cheaply than the traditional model. The honest caveat: the announcement names no drug candidates and offers no clinical data showing Formation’s AI systems have improved outcomes yet. The fund’s success will be judged on trial results over the next two to four years, not on the size of the raise. Everything AI, tested — this is one to check back on when the first acquired programs report data.
Frequently asked questions
What is Formation Bio’s new $600 million fund?
The Formation Bio Drug Development Accelerator Fund is a $600 million fund, backed by research foundations, endowments, hospitals and philanthropic organizations, that finances acquiring and developing clinical-stage drug programs inside Formation Bio’s portfolio.
How many drugs will the fund support?
Formation Bio plans to acquire or in-license 10 to 15 drug programs over the next three to five years, mainly Phase 1 and Phase 2 assets, targeting major clinical milestones within two to four years of each acquisition.
How is this different from other AI drug companies?
Most AI drug companies focus on discovering new molecules. Formation Bio focuses on clinical development — buying existing clinical-stage programs and using its AI-native platform and operating infrastructure to advance them toward proof of concept.
Sources: Formation Bio via PR Newswire, Forbes, FirstWord Pharma, Wall Street Journal via TradingView.